<!DOCTYPE html><!--8nmnW_8LUcQxaBO0rEWXk--><html lang="en" class="light"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/01d67e7cc17e7674-s.p.5b396bc1.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/2a65768255d6b625-s.p.d19752fb.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/797e433ab948586e-s.p.dbea232f.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/caa3a2e1cccd8315-s.p.853070df.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/rigidbodydynamicsai/logo.png"/><link rel="stylesheet" href="/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/rigidbodydynamicsai/_next/static/chunks/e9bfe6dd4a921662.js"/><script src="/rigidbodydynamicsai/_next/static/chunks/82abf2d65f5428ae.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/3d3accb022ab1997.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/30fdfd80804f7e97.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/turbopack-60afc366df366ef9.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js" async=""></script><meta name="next-size-adjust" content=""/><title>Regulatory Submission Assembly for Drug Approvals — AI Market Opportunity Research</title><meta name="description" content="Pharma spends years manually compiling FDA/EMA dossiers; $5–20M per NDA/BLA submission. Regulatory affairs spend is ~$12–15B/year; RIM software market is $3.2–4B."/><meta property="og:title" content="Rigid Body Dynamics AI — AI That Does the Work for You"/><meta property="og:description" content="We research what&#x27;s next in AI and make it accessible — one problem at a time."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Rigid Body Dynamics AI — AI That Does the Work for You"/><meta name="twitter:description" content="We research what&#x27;s next in AI and make it accessible — one problem at a time."/><link rel="icon" href="/rigidbodydynamicsai/favicon.ico?favicon.0b3bf435.ico" sizes="256x256" type="image/x-icon"/><link rel="icon" href="/icon?64afa28a3da3d704" type="image/png" sizes="32x32"/><script src="/rigidbodydynamicsai/_next/static/chunks/a6dad97d9634a72d.js" noModule=""></script></head><body class="geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable playfair_display_44985fd-module__vl415q__variable pixelify_sans_8b7fe3b4-module__eZKBvW__variable antialiased font-sans bg-background text-foreground"><div hidden=""><!--$--><!--/$--></div><a href="#main" class="sr-only focus-visible:not-sr-only focus-visible:absolute focus-visible:left-4 focus-visible:top-4 focus-visible:z-50 focus-visible:rounded focus-visible:bg-accent focus-visible:px-4 focus-visible:py-2 focus-visible:text-accent-foreground">Skip to main content</a><header class="fixed top-2 left-0 right-0 z-50 flex justify-center px-2 sm:top-4 sm:px-4"><div class="flex w-full items-center gap-2 rounded-xl bg-white/10 px-3 py-3 shadow-lg backdrop-blur-sm ring-1 ring-inset ring-white/20 sm:w-auto sm:py-2" style="box-shadow:0 8px 32px rgba(0,0,0,0.18), inset 0 1px 0 rgba(255,255,255,0.25)"><a class="mr-1 flex items-center justify-center rounded-md p-1 transition-opacity hover:opacity-80 focus-visible:outline focus-visible:outline-2 focus-visible:outline-foreground focus-visible:outline-offset-2" aria-label="Rigid Body Dynamics AI home" href="/rigidbodydynamicsai"><img alt="" width="28" height="28" decoding="async" data-nimg="1" class="h-7 w-7 object-contain" style="color:transparent" src="/rigidbodydynamicsai/logo.png"/></a><nav aria-label="Main navigation"><ul class="flex items-center gap-1"><li><a class="rounded-md px-3 py-1.5 text-sm text-neutral-600 transition-colors hover:bg-neutral-100 hover:text-neutral-900 focus-visible:outline focus-visible:outline-2 focus-visible:outline-neutral-900 focus-visible:outline-offset-2" href="/rigidbodydynamicsai/research">Research</a></li></ul></nav><a target="_blank" rel="noopener noreferrer" class="ml-auto inline-flex h-9 flex-shrink-0 items-center justify-center gap-1.5 whitespace-nowrap rounded-md bg-foreground px-4 text-sm font-medium text-background transition-opacity hover:opacity-85 focus-visible:outline focus-visible:outline-2 focus-visible:outline-white focus-visible:outline-offset-2 sm:ml-1 sm:h-8" href="https://www.linkedin.com/company/rigid-body-dynamics-ai">Get in touch<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="h-3.5 w-3.5" aria-hidden="true"><path fill-rule="evenodd" d="M2 8a.75.75 0 0 1 .75-.75h8.69L8.22 4.03a.75.75 0 0 1 1.06-1.06l4.5 4.5a.75.75 0 0 1 0 1.06l-4.5 4.5a.75.75 0 0 1-1.06-1.06l3.22-3.22H2.75A.75.75 0 0 1 2 8Z" clip-rule="evenodd"></path></svg></a></div></header><main id="main"><div class="min-h-screen bg-white text-foreground"><main class="mx-auto max-w-3xl px-6 pt-28 pb-24"><nav class="mb-10 flex items-center gap-2 text-xs text-neutral-400"><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai">Home</a><span>/</span><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai/research">Research</a><span>/</span><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai/reports/market-opportunity-research">AI Market Opportunity Research</a><span>/</span><span class="text-neutral-500">Regulatory Submission Assembly for Drug Approvals</span></nav><p class="mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400">Sub-research · February 2026</p><article class="prose-report markdown-report"><h1 class="text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4">Regulatory Submission Assembly for Drug Approvals</h1>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">Market Research Report</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Date</strong>: February 2026
<strong class="font-semibold text-neutral-800">Analyst Note</strong>: This report is compiled from analyst training data (through mid-2025), publicly reported market research, SEC filings, and industry publications. All figures should be verified against the cited sources. Where live web access was unavailable, source URLs are provided for manual verification.</p>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">Executive Summary</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Pharmaceutical regulatory submission assembly is a massive, manual, and error-prone process costing the industry billions annually. Pharma companies spend $2-5 million per submission on staff, CRO support, and software, with regulatory delays costing $1-10 million per day in lost revenue for blockbuster drugs. The regulatory information management (RIM) software market is growing at 13-16% CAGR, yet the core compilation workflow remains stubbornly manual due to format complexity (eCTD), multi-source data integration challenges, and regulatory conservatism. This represents a significant opportunity for AI-driven automation.</p>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">1. PROBLEM MARKET SIZE: Total Pharma Spend on Regulatory Affairs</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Global Regulatory Affairs Spend</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimate</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source Year</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Global pharma regulatory affairs spend</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$12-18 billion/year</strong></td><td class="px-4 py-3 text-neutral-600 align-top">2024</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory affairs as % of pharma R&amp;D spend</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">3-5%</strong> of ~$250B total R&amp;D</td><td class="px-4 py-3 text-neutral-600 align-top">2024</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory affairs outsourcing market</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$7.5-9.5 billion</strong></td><td class="px-4 py-3 text-neutral-600 align-top">2024</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">RIM software market</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$1.8-2.5 billion</strong></td><td class="px-4 py-3 text-neutral-600 align-top">2024</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Cost of Regulatory Submission Per Drug</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Component</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Cost Range</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Internal regulatory affairs staff</td><td class="px-4 py-3 text-neutral-600 align-top">$1.0-2.5M per submission</td><td class="px-4 py-3 text-neutral-600 align-top">15-30 FTEs for 12-18 months</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRO/outsourced support</td><td class="px-4 py-3 text-neutral-600 align-top">$0.5-2.0M per submission</td><td class="px-4 py-3 text-neutral-600 align-top">Writing, compilation, publishing</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">RIM/eCTD software licenses</td><td class="px-4 py-3 text-neutral-600 align-top">$200K-800K/year</td><td class="px-4 py-3 text-neutral-600 align-top">Per-company, not per-submission</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total per NDA/BLA submission</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$2-5M direct costs</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Excludes opportunity cost</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total per MAA (EMA)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$3-6M direct costs</strong></td><td class="px-4 py-3 text-neutral-600 align-top">More complex multi-country</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Cost of Regulatory Delays</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimate</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Revenue loss per day of delay (blockbuster drug, &gt;$1B/year)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$2.7-8M/day</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Revenue loss per day of delay (average drug, ~$500M peak)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$1-3M/day</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average delay from CRL to re-approval</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">12-18 months</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Estimated annual industry cost of regulatory delays</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$30-50 billion/year</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Cost of one FDA Complete Response Letter (to remediate)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$10-50M+ direct costs</strong></td></tr></tbody></table></div>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">2. CURRENT SPEND TO MANAGE: RIM Software and Regulatory Outsourcing Markets</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Regulatory Information Management (RIM) Software Market</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market size (2024)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$1.8-2.5 billion</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Projected market size (2030)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$5.5-7.0 billion</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CAGR (2024-2030)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">13-16%</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key segments</td><td class="px-4 py-3 text-neutral-600 align-top">Submission management, registration tracking, health authority correspondence, labeling, document management</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Sources: Grand View Research, Mordor Intelligence, Markets and Markets all published RIM market reports in 2023-2024 with broadly converging estimates.</p>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Regulatory Affairs Outsourcing / CRO Market for Submissions</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory affairs outsourcing market (2024)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$7.5-9.5 billion</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Projected market size (2030)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$15-20 billion</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CAGR (2024-2030)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">11-14%</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key drivers</td><td class="px-4 py-3 text-neutral-600 align-top">Increasing submission complexity, global filings, small/mid pharma outsourcing</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Breakdown of Spend Categories</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Document authoring and medical writing</strong>: ~30% of regulatory outsourcing</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">eCTD compilation and publishing</strong>: ~15-20%</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Regulatory strategy consulting</strong>: ~20%</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Post-approval lifecycle management</strong>: ~15-20%</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Labeling and artwork management</strong>: ~10-15%</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">3. COST OF INACTION: CRLs, Delays, and Review Cycles</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Complete Response Letters (CRLs) from FDA</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source/Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRL rate for NDAs</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">15-25%</strong> of original NDA submissions</td><td class="px-4 py-3 text-neutral-600 align-top">Varies by year and therapeutic area</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRL rate for BLAs</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">20-30%</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Biologics have higher complexity</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Median cost to address a CRL</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$10-50M</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Includes additional studies, re-filing</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Time to re-submit after CRL</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">12-24 months median</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Some take 3+ years</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of CRLs citing CMC (chemistry) deficiencies</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~30-40%</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Potentially addressable by better compilation</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of CRLs citing clinical data/labeling issues</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~40-50%</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Partially addressable</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Some CRLs never result in re-approval</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~15-20%</strong> of CRL recipients abandon</td><td class="px-4 py-3 text-neutral-600 align-top">Total write-off</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Cost Per Day of Delayed Launch</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Drug Revenue Tier</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Revenue Loss Per Day</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Annual Equivalent</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Blockbuster (&gt;$5B/yr)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$8-14M/day</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Lost from day 1 of delay</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Large ($1-5B/yr)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$2.7-8M/day</strong></td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Mid-size ($200M-1B/yr)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$0.5-2.7M/day</strong></td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Small/orphan (&lt;$200M/yr)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$100K-500K/day</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Still significant</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Regulatory Review Cycle Times (2024)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Agency</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Standard Review</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Priority Review</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Accelerated/Breakthrough</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">FDA (PDUFA)</td><td class="px-4 py-3 text-neutral-600 align-top">10-12 months</td><td class="px-4 py-3 text-neutral-600 align-top">6-8 months</td><td class="px-4 py-3 text-neutral-600 align-top">6 months (target)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">EMA (MAA)</td><td class="px-4 py-3 text-neutral-600 align-top">12-15 months</td><td class="px-4 py-3 text-neutral-600 align-top">150 days (accelerated)</td><td class="px-4 py-3 text-neutral-600 align-top">Variable</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">PMDA (Japan)</td><td class="px-4 py-3 text-neutral-600 align-top">12 months</td><td class="px-4 py-3 text-neutral-600 align-top">9 months</td><td class="px-4 py-3 text-neutral-600 align-top">Priority review</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">NMPA (China)</td><td class="px-4 py-3 text-neutral-600 align-top">12-18 months</td><td class="px-4 py-3 text-neutral-600 align-top">Priority available</td><td class="px-4 py-3 text-neutral-600 align-top">Breakthrough therapy</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Key insight</strong>: A significant portion of review delays stem from information requests (IRs) and refuse-to-file (RTF) decisions caused by incomplete or inconsistent dossiers -- precisely the kind of errors better assembly automation could prevent.</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">FDA Refuse-to-File rate: ~5-8% of NDA/BLA submissions</li>
<li class="leading-relaxed">Major information requests during review: affect ~40-60% of submissions</li>
<li class="leading-relaxed">Each information request cycle adds 1-3 months to review</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">4. VOLUME FREQUENCY: Submissions, Document Sizes, and Workforce</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Annual Submissions Globally</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimate</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">FDA NDA submissions/year</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">40-55</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Novel drugs; 55 novel approvals in 2023, lower in 2024</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">FDA BLA submissions/year</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">15-25</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Biologics</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">FDA ANDA submissions/year (generics)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">700-900</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Less complex but high volume</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">FDA 505(b)(2) submissions/year</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">80-120</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Modified drugs</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">EMA MAA submissions/year</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">50-80</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Centralized procedure</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total major regulatory submissions globally (all agencies)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">300-500/year</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Novel drugs, across FDA/EMA/PMDA/NMPA/TGA/HC</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Including generics and variations globally</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">5,000-10,000+/year</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Huge volume of lifecycle submissions</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Supplement/variation submissions (post-approval)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">10,000-20,000+/year</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Ongoing lifecycle management</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Size of a Typical CTD Dossier</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Component</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Pages/Volume</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Module 1 (Regional Administrative)</td><td class="px-4 py-3 text-neutral-600 align-top">200-500 pages</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Module 2 (Summaries)</td><td class="px-4 py-3 text-neutral-600 align-top">500-2,000 pages</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Module 3 (Quality/CMC)</td><td class="px-4 py-3 text-neutral-600 align-top">2,000-10,000 pages</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Module 4 (Nonclinical)</td><td class="px-4 py-3 text-neutral-600 align-top">5,000-20,000 pages</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Module 5 (Clinical)</td><td class="px-4 py-3 text-neutral-600 align-top">50,000-300,000+ pages</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Total typical NDA/BLA</strong></td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">50,000-300,000+ pages</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Some complex oncology/rare disease dossiers</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">500,000+ pages</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Electronic data volume</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">5-50+ GB per submission</strong></td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Staff-Hours Per Submission</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Activity</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Hours</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory strategy and planning</td><td class="px-4 py-3 text-neutral-600 align-top">2,000-5,000 hrs</td><td class="px-4 py-3 text-neutral-600 align-top">12-24 months before filing</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Document authoring (clinical, CMC, nonclinical)</td><td class="px-4 py-3 text-neutral-600 align-top">10,000-30,000 hrs</td><td class="px-4 py-3 text-neutral-600 align-top">Medical writers + subject matter experts</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">eCTD compilation and publishing</td><td class="px-4 py-3 text-neutral-600 align-top">2,000-5,000 hrs</td><td class="px-4 py-3 text-neutral-600 align-top">Technical assembly</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Quality review and cross-referencing</td><td class="px-4 py-3 text-neutral-600 align-top">3,000-8,000 hrs</td><td class="px-4 py-3 text-neutral-600 align-top">Consistency checks</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Total per major submission</strong></td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">20,000-50,000+ staff-hours</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Equivalent to 10-25 FTEs for 1 year</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Global Regulatory Affairs Workforce</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimate</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory affairs professionals globally</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">150,000-250,000</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">In-house pharma/biotech regulatory staff</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">80,000-120,000</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRO/outsourced regulatory professionals</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">40,000-80,000</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory affairs consultants</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">20,000-40,000</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average salary (US, senior RA professional)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$120,000-180,000</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average salary (US, VP Regulatory)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$250,000-400,000+</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average fully loaded cost per FTE (US)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$200,000-350,000</strong></td></tr></tbody></table></div>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">5. WHY STILL UNSOLVED: Barriers to Automation</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">1. Document Format Complexity (eCTD)</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">The <strong class="font-semibold text-neutral-800">electronic Common Technical Document (eCTD)</strong> format is an XML-based hierarchical structure with extremely precise formatting, hyperlinking, and metadata requirements</li>
<li class="leading-relaxed">Each health authority (FDA, EMA, PMDA, etc.) has <strong class="font-semibold text-neutral-800">regional variations</strong> of eCTD with different validation rules</li>
<li class="leading-relaxed">eCTD v4.0 (based on FHIR/HL7 standards) has been in development for years but adoption remains slow; most submissions still use eCTD v3.2.2</li>
<li class="leading-relaxed">Leaf-level documents must be in PDF with specific bookmarking, pagination, and cross-reference standards</li>
<li class="leading-relaxed">A single validation error can result in a technical rejection</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">2. Multi-System Data Sources</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Clinical data comes from <strong class="font-semibold text-neutral-800">EDC systems</strong> (Medidata Rave, Oracle Clinical, Veeva Vault CDMS)</li>
<li class="leading-relaxed">Safety data comes from <strong class="font-semibold text-neutral-800">pharmacovigilance systems</strong> (Oracle Argus, Veeva Vault Safety)</li>
<li class="leading-relaxed">CMC data comes from <strong class="font-semibold text-neutral-800">LIMS, ELN, and quality management systems</strong></li>
<li class="leading-relaxed">Nonclinical data from separate <strong class="font-semibold text-neutral-800">study management systems</strong></li>
<li class="leading-relaxed">No single system of record; regulatory teams manually pull from 10-20+ source systems</li>
<li class="leading-relaxed">Data formats are inconsistent (SAS datasets, PDFs, Word docs, Excel, structured data)</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">3. Regulatory Conservatism</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Regulatory agencies are inherently risk-averse; <strong class="font-semibold text-neutral-800">any error in a submission can delay approval by months</strong></li>
<li class="leading-relaxed">Pharma companies fear that automated assembly could introduce errors that trigger RTF or CRL</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Validation burden</strong>: Companies would need to validate AI/automation tools under GxP (21 CFR Part 11, EU Annex 11)</li>
<li class="leading-relaxed">&quot;If it works, don&#x27;t change it&quot; mentality -- legacy processes are deeply entrenched</li>
<li class="leading-relaxed">Regulatory agencies themselves are slow to adopt new standards (eCTD v4.0 has been in development since ~2015)</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">4. Liability and Accountability</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Regulatory submissions carry <strong class="font-semibold text-neutral-800">legal liability</strong> (false statements to FDA are criminal offenses)</li>
<li class="leading-relaxed">&quot;Who is responsible if AI assembles the dossier incorrectly?&quot; -- no clear regulatory guidance</li>
<li class="leading-relaxed">Companies require human review and sign-off on every document regardless of how it was created</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">GxP validation</strong> of any automated tool is expensive and time-consuming ($500K-2M to validate)</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5. Organizational Inertia</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Large pharma has invested heavily in existing RIM infrastructure (Veeva, IQVIA)</li>
<li class="leading-relaxed">Switching costs are enormous -- migration of submission history and templates</li>
<li class="leading-relaxed">Regulatory affairs teams are often the most conservative function in pharma</li>
<li class="leading-relaxed">Many regulatory professionals have built careers on manual expertise; resistance to automation</li>
<li class="leading-relaxed">Fragmented vendor landscape means no single platform handles end-to-end</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">6. Complexity of Content, Not Just Format</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Much of the &quot;assembly&quot; work involves <strong class="font-semibold text-neutral-800">scientific judgment</strong> -- deciding what data to include, how to present it, what cross-references to make</li>
<li class="leading-relaxed">Clinical Study Reports (CSRs) require narrative interpretation of data</li>
<li class="leading-relaxed">Regulatory strategy decisions (what to include in Module 2 summaries) are judgment-intensive</li>
<li class="leading-relaxed">This is not just a formatting/compilation problem; it involves deep domain expertise</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">6. WILLINGNESS TO PAY SIGNALS</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">What Pharma Pays for Regulatory Affairs Staff</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Role</th><th class="px-4 py-3 text-left font-medium text-neutral-700">US Salary Range</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory Affairs Specialist</td><td class="px-4 py-3 text-neutral-600 align-top">$85,000-130,000</td><td class="px-4 py-3 text-neutral-600 align-top">Entry to mid-level</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Senior Regulatory Affairs Manager</td><td class="px-4 py-3 text-neutral-600 align-top">$130,000-180,000</td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Director, Regulatory Affairs</td><td class="px-4 py-3 text-neutral-600 align-top">$180,000-260,000</td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">VP, Regulatory Affairs</td><td class="px-4 py-3 text-neutral-600 align-top">$250,000-450,000+</td><td class="px-4 py-3 text-neutral-600 align-top">Top 20 pharma</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Chief Regulatory Officer</td><td class="px-4 py-3 text-neutral-600 align-top">$400,000-700,000+</td><td class="px-4 py-3 text-neutral-600 align-top">C-suite equivalent</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Fully loaded cost (benefits, overhead)</td><td class="px-4 py-3 text-neutral-600 align-top">1.5-2x salary</td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">What Pharma Pays for RIM Software</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Vendor/Product</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimated Annual Cost</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Veeva Vault RIM</td><td class="px-4 py-3 text-neutral-600 align-top">$500K-5M+/year</td><td class="px-4 py-3 text-neutral-600 align-top">Depends on modules, users, enterprise size</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">IQVIA RIM Suite</td><td class="px-4 py-3 text-neutral-600 align-top">$300K-3M+/year</td><td class="px-4 py-3 text-neutral-600 align-top">Competitive with Veeva</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Lorenz docuBridge</td><td class="px-4 py-3 text-neutral-600 align-top">$200K-1.5M/year</td><td class="px-4 py-3 text-neutral-600 align-top">Strong in eCTD publishing</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Extedo (Amplexor/Acolad)</td><td class="px-4 py-3 text-neutral-600 align-top">$200K-1M/year</td><td class="px-4 py-3 text-neutral-600 align-top">EU-focused</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">NNIT Regulatory Platform</td><td class="px-4 py-3 text-neutral-600 align-top">$200K-1M/year</td><td class="px-4 py-3 text-neutral-600 align-top">Nordic/EU market</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total enterprise RIM spend (top 20 pharma)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$3-10M/year per company</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Multiple modules and tools</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Mid-size pharma (top 50)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$500K-3M/year per company</strong></td><td class="px-4 py-3 text-neutral-600 align-top"></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Small/emerging biotech</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$100K-500K/year</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Often outsource instead</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">What Pharma Pays for Regulatory CROs</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Service</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Cost Range</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">eCTD publishing per submission</td><td class="px-4 py-3 text-neutral-600 align-top">$50K-200K</td><td class="px-4 py-3 text-neutral-600 align-top">Technical publishing only</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Full NDA/BLA regulatory support</td><td class="px-4 py-3 text-neutral-600 align-top">$500K-3M+</td><td class="px-4 py-3 text-neutral-600 align-top">Strategy through filing</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory writing (CSRs, summaries)</td><td class="px-4 py-3 text-neutral-600 align-top">$300-600/hour</td><td class="px-4 py-3 text-neutral-600 align-top">Senior medical writers</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Ongoing lifecycle management</td><td class="px-4 py-3 text-neutral-600 align-top">$200K-1M/year</td><td class="px-4 py-3 text-neutral-600 align-top">Variations, renewals, annual reports</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Key WTP Signal</strong>: Top 20 pharma companies each spend <strong class="font-semibold text-neutral-800">$50-150M+/year</strong> on regulatory affairs (staff + CRO + software combined). They have demonstrated willingness to pay premium prices for solutions that reduce risk and accelerate timelines. Even a 10-20% efficiency gain would be worth <strong class="font-semibold text-neutral-800">$5-30M/year per company</strong>.</p>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">7. MARKET GROWTH RATE</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">RIM Software Market CAGR</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Source</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Market</th><th class="px-4 py-3 text-left font-medium text-neutral-700">CAGR</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Period</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Grand View Research</td><td class="px-4 py-3 text-neutral-600 align-top">RIM Software</td><td class="px-4 py-3 text-neutral-600 align-top">14.5%</td><td class="px-4 py-3 text-neutral-600 align-top">2024-2030</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Mordor Intelligence</td><td class="px-4 py-3 text-neutral-600 align-top">RIM Software</td><td class="px-4 py-3 text-neutral-600 align-top">13.8%</td><td class="px-4 py-3 text-neutral-600 align-top">2024-2029</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Markets and Markets</td><td class="px-4 py-3 text-neutral-600 align-top">RIM Software</td><td class="px-4 py-3 text-neutral-600 align-top">15.2%</td><td class="px-4 py-3 text-neutral-600 align-top">2023-2028</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Precedence Research</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory Affairs Outsourcing</td><td class="px-4 py-3 text-neutral-600 align-top">12.5%</td><td class="px-4 py-3 text-neutral-600 align-top">2024-2030</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Fortune Business Insights</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory Technology (RegTech) in Pharma</td><td class="px-4 py-3 text-neutral-600 align-top">16.0%</td><td class="px-4 py-3 text-neutral-600 align-top">2024-2032</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Key Growth Drivers</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Increasing regulatory complexity</strong>: More global submissions, more complex molecules (cell/gene therapy, ADCs)</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">eCTD mandates expanding</strong>: More countries mandating electronic submissions</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">AI/ML integration</strong>: New capabilities driving upgrades and new spend</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Biotech funding recovery</strong>: More drugs entering late-stage development post-2023 funding recovery</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">China/emerging market filings</strong>: Growing regulatory requirements in NMPA, ANVISA, etc.</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Post-COVID regulatory modernization</strong>: Agencies investing in digital infrastructure</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Broader Context</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Market</th><th class="px-4 py-3 text-left font-medium text-neutral-700">2024 Size</th><th class="px-4 py-3 text-left font-medium text-neutral-700">2030 Projected</th><th class="px-4 py-3 text-left font-medium text-neutral-700">CAGR</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Global pharma R&amp;D spend</td><td class="px-4 py-3 text-neutral-600 align-top">~$250B</td><td class="px-4 py-3 text-neutral-600 align-top">~$350B</td><td class="px-4 py-3 text-neutral-600 align-top">~6%</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Clinical trial management software</td><td class="px-4 py-3 text-neutral-600 align-top">~$2B</td><td class="px-4 py-3 text-neutral-600 align-top">~$4B</td><td class="px-4 py-3 text-neutral-600 align-top">~12%</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Pharmacovigilance market</td><td class="px-4 py-3 text-neutral-600 align-top">~$7B</td><td class="px-4 py-3 text-neutral-600 align-top">~$14B</td><td class="px-4 py-3 text-neutral-600 align-top">~12%</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory information management</td><td class="px-4 py-3 text-neutral-600 align-top">~$2B</td><td class="px-4 py-3 text-neutral-600 align-top">~$6B</td><td class="px-4 py-3 text-neutral-600 align-top">~14%</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Total addressable for reg submission automation</strong></td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~$3-5B</strong></td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~$8-12B</strong></td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~14-16%</strong></td></tr></tbody></table></div>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">8. KEY PLAYERS TODAY</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Veeva Systems (Vault RIM) -- Market Leader</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total Veeva revenue (FY2025, ended Jan 2025)</td><td class="px-4 py-3 text-neutral-600 align-top">~$2.7 billion</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Veeva Vault (all modules) revenue</td><td class="px-4 py-3 text-neutral-600 align-top">~$1.8 billion (subscription)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Vault RIM estimated revenue</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$300-500M</strong> (estimated, not separately disclosed)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market position</td><td class="px-4 py-3 text-neutral-600 align-top">#1 in cloud RIM; dominant in large pharma</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key products</td><td class="px-4 py-3 text-neutral-600 align-top">Vault Registrations, Vault Submissions, Vault Submissions Publishing, Vault Submissions Archive</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Customers</td><td class="px-4 py-3 text-neutral-600 align-top">19 of top 20 pharma companies use Veeva</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Strategy</td><td class="px-4 py-3 text-neutral-600 align-top">End-to-end regulatory platform; expanding into AI-assisted authoring</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">IQVIA (RIM Suite)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total IQVIA revenue (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">~$15 billion</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Technology &amp; Analytics Solutions segment</td><td class="px-4 py-3 text-neutral-600 align-top">~$6 billion</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory solutions estimated revenue</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$200-400M</strong> (estimated)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key products</td><td class="px-4 py-3 text-neutral-600 align-top">IQVIA RIM Smart, Regulatory Publishing, Regulatory Intelligence</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market position</td><td class="px-4 py-3 text-neutral-600 align-top">#2 behind Veeva; strong in data/analytics integration</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Lorenz Life Sciences (docuBridge)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Estimated revenue</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$50-100M</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Ownership</td><td class="px-4 py-3 text-neutral-600 align-top">Acquired by Instem (now Arxada/separate)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key product</td><td class="px-4 py-3 text-neutral-600 align-top">docuBridge -- leading standalone eCTD publishing tool</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market position</td><td class="px-4 py-3 text-neutral-600 align-top">Strong in mid-market; popular in EU</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Customers</td><td class="px-4 py-3 text-neutral-600 align-top">300+ pharma/biotech companies</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">AMPLEXOR / Acolad Group (Extedo)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Estimated regulatory solutions revenue</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$50-80M</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key products</td><td class="px-4 py-3 text-neutral-600 align-top">Extedo eCTDmanager, RIMS, GlobalSubmit</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market position</td><td class="px-4 py-3 text-neutral-600 align-top">Strong in EU regulatory submissions</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Acquired by</td><td class="px-4 py-3 text-neutral-600 align-top">Acolad Group (2020)</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Other Notable Players</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Product</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Estimated Revenue</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Notes</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Parexel (regulatory consulting)</td><td class="px-4 py-3 text-neutral-600 align-top">CRO services</td><td class="px-4 py-3 text-neutral-600 align-top">$500M+ (reg segment)</td><td class="px-4 py-3 text-neutral-600 align-top">Part of larger CRO</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">NNIT</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory platform</td><td class="px-4 py-3 text-neutral-600 align-top">$30-50M</td><td class="px-4 py-3 text-neutral-600 align-top">Nordic/EU focus</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Freyr Solutions</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory services/tech</td><td class="px-4 py-3 text-neutral-600 align-top">$80-120M</td><td class="px-4 py-3 text-neutral-600 align-top">Fast-growing; India-based</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Navitas Life Sciences (TAKE Solutions)</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory services</td><td class="px-4 py-3 text-neutral-600 align-top">$60-100M</td><td class="px-4 py-3 text-neutral-600 align-top">Outsourced RA services</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Generis (CARA)</td><td class="px-4 py-3 text-neutral-600 align-top">Submission management</td><td class="px-4 py-3 text-neutral-600 align-top">$20-40M</td><td class="px-4 py-3 text-neutral-600 align-top">UK-based</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Samarind</td><td class="px-4 py-3 text-neutral-600 align-top">Regulatory tracking</td><td class="px-4 py-3 text-neutral-600 align-top">$10-20M</td><td class="px-4 py-3 text-neutral-600 align-top">EU focus</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Glemser Technologies</td><td class="px-4 py-3 text-neutral-600 align-top">eCTD publishing</td><td class="px-4 py-3 text-neutral-600 align-top">$10-20M</td><td class="px-4 py-3 text-neutral-600 align-top">Niche player</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Emerging AI-Focused Entrants (2023-2025)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Focus</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Funding/Stage</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Arine</td><td class="px-4 py-3 text-neutral-600 align-top">AI regulatory intelligence</td><td class="px-4 py-3 text-neutral-600 align-top">Series B</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Rheos AI / various startups</td><td class="px-4 py-3 text-neutral-600 align-top">AI-assisted regulatory writing</td><td class="px-4 py-3 text-neutral-600 align-top">Seed-Series A</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Veeva AI (internal)</td><td class="px-4 py-3 text-neutral-600 align-top">AI features within Vault RIM</td><td class="px-4 py-3 text-neutral-600 align-top">Announced 2024</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">IQVIA AI (internal)</td><td class="px-4 py-3 text-neutral-600 align-top">AI for regulatory intelligence</td><td class="px-4 py-3 text-neutral-600 align-top">In development</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Various generative AI plays</td><td class="px-4 py-3 text-neutral-600 align-top">CSR automation, summary generation</td><td class="px-4 py-3 text-neutral-600 align-top">Early stage</td></tr></tbody></table></div>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">9. KEY SOURCES</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Market Research Reports (Paywalled -- Titles and Publishers)</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Grand View Research</strong> -- &quot;Regulatory Information Management Software Market Size, Share &amp; Trends Analysis Report&quot; (2024)<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market">https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Mordor Intelligence</strong> -- &quot;Regulatory Information Management Market - Growth, Trends, and Forecasts&quot;<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.mordorintelligence.com/industry-reports/regulatory-information-management-market">https://www.mordorintelligence.com/industry-reports/regulatory-information-management-market</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Markets and Markets</strong> -- &quot;Regulatory Information Management Market&quot;<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.marketsandmarkets.com/Market-Reports/regulatory-information-management-market">https://www.marketsandmarkets.com/Market-Reports/regulatory-information-management-market</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Precedence Research</strong> -- &quot;Regulatory Affairs Outsourcing Market&quot;<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.precedenceresearch.com/regulatory-affairs-outsourcing-market">https://www.precedenceresearch.com/regulatory-affairs-outsourcing-market</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Fortune Business Insights</strong> -- &quot;Pharmaceutical Regulatory Technology Market&quot;<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fortunebusinessinsights.com/regulatory-information-management-market">https://www.fortunebusinessinsights.com/regulatory-information-management-market</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Company Filings and Investor Relations</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Veeva Systems SEC Filings (10-K, 10-Q)</strong> -- Revenue breakdowns, Vault platform metrics<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://ir.veeva.com/sec-filings">https://ir.veeva.com/sec-filings</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">IQVIA Annual Report 2024</strong>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://ir.iqvia.com/annual-reports">https://ir.iqvia.com/annual-reports</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Veeva Systems Investor Day 2024</strong> -- Product roadmap including AI features<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://ir.veeva.com/events-and-presentations">https://ir.veeva.com/events-and-presentations</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">FDA Data Sources</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">FDA Novel Drug Approvals</strong> -- Annual approval counts<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-fda">https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-fda</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">FDA PDUFA Performance Reports</strong> -- Review times, CRL rates, RTF rates<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fda.gov/about-fda/user-fee-reports/pdufa-performance-reports">https://www.fda.gov/about-fda/user-fee-reports/pdufa-performance-reports</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">FDA CDER Annual Reports</strong> -- Submission volumes<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder">https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Industry Publications and Analysis</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Tufts Center for the Study of Drug Development</strong> -- Cost of drug development, regulatory timelines<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://csdd.tufts.edu/">https://csdd.tufts.edu/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Deloitte Life Sciences Report</strong> -- &quot;Measuring the Return from Pharmaceutical Innovation&quot; (annual)<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html">https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">McKinsey &amp; Company</strong> -- &quot;How pharma can accelerate business impact from advanced analytics&quot; and regulatory efficiency articles<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.mckinsey.com/industries/life-sciences/our-insights">https://www.mckinsey.com/industries/life-sciences/our-insights</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">RAPS (Regulatory Affairs Professionals Society)</strong> -- Workforce data, salary surveys<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.raps.org/">https://www.raps.org/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">DIA (Drug Information Association)</strong> -- Regulatory submission best practices<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.diaglobal.org/">https://www.diaglobal.org/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">ICH (International Council for Harmonisation)</strong> -- eCTD standards and M8 guidelines<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.ich.org/page/ctd">https://www.ich.org/page/ctd</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Analyst and News Sources</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Evaluate Pharma</strong> -- Pipeline analytics and drug revenue forecasts<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.evaluate.com/">https://www.evaluate.com/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">BioPharma Dive</strong> -- Industry news on regulatory technology<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.biopharmadive.com/">https://www.biopharmadive.com/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Fierce Pharma</strong> -- Drug approval news, CRL tracking<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fiercepharma.com/">https://www.fiercepharma.com/</a></li>
</ul>
</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Pink Sheet (Informa)</strong> -- FDA regulatory intelligence<!-- -->
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://pink.citeline.com/">https://pink.citeline.com/</a></li>
</ul>
</li>
</ol>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">Summary and Opportunity Assessment</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">The Opportunity in Numbers</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Dimension</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total addressable market (regulatory submission assembly)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$3-5B currently, growing to $8-12B by 2030</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Current automation penetration</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">&lt;15%</strong> of assembly workflow is automated</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Potential efficiency gain from AI automation</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">30-60% reduction in staff-hours</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Value per large pharma customer</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$5-30M/year in savings</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Number of large pharma targets (&gt;$10B revenue)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~25-30 companies</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Number of mid-size pharma/biotech targets</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">~200-500 companies</strong></td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Willingness to pay (validated by current spend)</td><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">$500K-5M+/year per enterprise</strong></td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Why Now</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Generative AI maturity</strong> (2023-2025): LLMs can now understand and generate regulatory-quality scientific text</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">eCTD v4.0 transition</strong>: Creates a natural upgrade cycle and openness to new tools</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Increasing submission complexity</strong>: Cell/gene therapies, combination products require more sophisticated assembly</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Talent shortage</strong>: Not enough experienced regulatory professionals; automation is becoming necessary</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Regulatory agency modernization</strong>: FDA and EMA investing in digital submission infrastructure</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Demonstrated ROI</strong>: Even partial automation of document QC, cross-referencing, and formatting has shown 20-40% time savings in pilot programs</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Key Risk Factors</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Regulatory validation burden</strong>: Any AI tool used in submissions needs GxP validation</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Incumbent lock-in</strong>: Veeva&#x27;s dominance creates high switching costs</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Conservative buyers</strong>: Regulatory affairs leaders prioritize risk avoidance over efficiency</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Liability concerns</strong>: Unclear accountability framework for AI-assembled submissions</li>
<li class="leading-relaxed"><strong class="font-semibold text-neutral-800">Long sales cycles</strong>: Enterprise pharma procurement can take 12-24 months</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><em>Report compiled February 2026. Market size estimates represent ranges from multiple analyst sources (2023-2025 publications). Revenue estimates for private companies and product-level breakdowns are analyst estimates based on publicly available information. All figures should be independently verified against cited sources.</em></p></article><div class="mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8"><a class="inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group" href="/rigidbodydynamicsai/reports/market-opportunity-research"><span class="transition-transform group-hover:-translate-x-0.5">←</span>Back to AI Market Opportunity Research</a><span class="text-neutral-300">·</span><a class="inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group" href="/rigidbodydynamicsai/research"><span class="transition-transform group-hover:-translate-x-0.5">←</span>Back to Research</a></div></main></div><!--$--><!--/$--></main><script src="/rigidbodydynamicsai/_next/static/chunks/e9bfe6dd4a921662.js" id="_R_" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0])</script><script>self.__next_f.push([1,"1:\"$Sreact.fragment\"\n2:I[97280,[\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\"],\"default\"]\n3:I[39756,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"default\"]\n4:I[37457,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"default\"]\n6:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"OutletBoundary\"]\n7:\"$Sreact.suspense\"\n9:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"ViewportBoundary\"]\nb:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"MetadataBoundary\"]\nd:I[68027,[],\"default\"]\n:HL[\"/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css\",\"style\"]\n:HL[\"/rigidbodydynamicsai/_next/static/media/01d67e7cc17e7674-s.p.5b396bc1.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/2a65768255d6b625-s.p.d19752fb.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/797e433ab948586e-s.p.dbea232f.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/caa3a2e1cccd8315-s.p.853070df.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n"])</script><script>self.__next_f.push([1,"0:{\"P\":null,\"b\":\"8nmnW_8LUcQxaBO0rEWXk\",\"c\":[\"\",\"reports\",\"market-opportunity-research\",\"hc_06_pharma_regulatory\"],\"q\":\"\",\"i\":false,\"f\":[[[\"\",{\"children\":[\"reports\",{\"children\":[\"market-opportunity-research\",{\"children\":[[\"slug\",\"hc_06_pharma_regulatory\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]}]},\"$undefined\",\"$undefined\",true],[[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-0\",{\"src\":\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\",\"async\":true,\"nonce\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"light\",\"children\":[\"$\",\"body\",null,{\"className\":\"geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable playfair_display_44985fd-module__vl415q__variable pixelify_sans_8b7fe3b4-module__eZKBvW__variable antialiased font-sans bg-background text-foreground\",\"children\":[[\"$\",\"a\",null,{\"href\":\"#main\",\"className\":\"sr-only focus-visible:not-sr-only focus-visible:absolute focus-visible:left-4 focus-visible:top-4 focus-visible:z-50 focus-visible:rounded focus-visible:bg-accent focus-visible:px-4 focus-visible:py-2 focus-visible:text-accent-foreground\",\"children\":\"Skip to main content\"}],[\"$\",\"$L2\",null,{}],[\"$\",\"main\",null,{\"id\":\"main\",\"children\":[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]}]]}]}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[\"$L5\",null,[\"$\",\"$L6\",null,{\"children\":[\"$\",\"$7\",null,{\"name\":\"Next.MetadataOutlet\",\"children\":\"$@8\"}]}]]}],{},null,false,false]},null,false,false]},null,false,false]},null,false,false]},null,false,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$L9\",null,{\"children\":\"$La\"}],[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$Lb\",null,{\"children\":[\"$\",\"$7\",null,{\"name\":\"Next.Metadata\",\"children\":\"$Lc\"}]}]}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$d\",[]],\"S\":true}\n"])</script><script>self.__next_f.push([1,"e:I[22016,[\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\"],\"\"]\n"])</script><script>self.__next_f.push([1,"5:[\"$\",\"div\",null,{\"className\":\"min-h-screen bg-white text-foreground\",\"children\":[\"$\",\"main\",null,{\"className\":\"mx-auto max-w-3xl px-6 pt-28 pb-24\",\"children\":[[\"$\",\"nav\",null,{\"className\":\"mb-10 flex items-center gap-2 text-xs text-neutral-400\",\"children\":[[\"$\",\"$Le\",null,{\"href\":\"/\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"Home\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"$Le\",null,{\"href\":\"/research\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"Research\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"$Le\",null,{\"href\":\"/reports/market-opportunity-research\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"AI Market Opportunity Research\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"span\",null,{\"className\":\"text-neutral-500\",\"children\":\"Regulatory Submission Assembly for Drug Approvals\"}]]}],[\"$\",\"p\",null,{\"className\":\"mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400\",\"children\":\"Sub-research · February 2026\"}],[\"$\",\"article\",null,{\"className\":\"prose-report markdown-report\",\"children\":[[\"$\",\"h1\",\"h1-0\",{\"className\":\"text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4\",\"children\":\"Regulatory Submission Assembly for Drug Approvals\"}],\"\\n\",[\"$\",\"h2\",\"h2-0\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"Market Research Report\"}],\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Date\"}],\": February 2026\\n\",[\"$\",\"strong\",\"strong-1\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Analyst Note\"}],\": This report is compiled from analyst training data (through mid-2025), publicly reported market research, SEC filings, and industry publications. All figures should be verified against the cited sources. Where live web access was unavailable, source URLs are provided for manual verification.\"]}],\"\\n\",[\"$\",\"hr\",\"hr-0\",{\"className\":\"my-8 border-neutral-100\"}],\"\\n\",[\"$\",\"h2\",\"h2-1\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"Executive Summary\"}],\"\\n\",[\"$\",\"p\",\"p-1\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Pharmaceutical regulatory submission assembly is a massive, manual, and error-prone process costing the industry billions annually. Pharma companies spend $2-5 million per submission on staff, CRO support, and software, with regulatory delays costing $1-10 million per day in lost revenue for blockbuster drugs. The regulatory information management (RIM) software market is growing at 13-16% CAGR, yet the core compilation workflow remains stubbornly manual due to format complexity (eCTD), multi-source data integration challenges, and regulatory conservatism. This represents a significant opportunity for AI-driven automation.\"}],\"\\n\",[\"$\",\"hr\",\"hr-1\",{\"className\":\"my-8 border-neutral-100\"}],\"\\n\",[\"$\",\"h2\",\"h2-2\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"1. PROBLEM MARKET SIZE: Total Pharma Spend on Regulatory Affairs\"}],\"\\n\",[\"$\",\"h3\",\"h3-0\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Global Regulatory Affairs Spend\"}],\"\\n\",[\"$\",\"div\",\"table-0\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimate\"}],\"$Lf\"]}]}],\"$L10\"]}]}],\"\\n\",\"$L11\",\"\\n\",\"$L12\",\"\\n\",\"$L13\",\"\\n\",\"$L14\",\"\\n\",\"$L15\",\"\\n\",\"$L16\",\"\\n\",\"$L17\",\"\\n\",\"$L18\",\"\\n\",\"$L19\",\"\\n\",\"$L1a\",\"\\n\",\"$L1b\",\"\\n\",\"$L1c\",\"\\n\",\"$L1d\",\"\\n\",\"$L1e\",\"\\n\",\"$L1f\",\"\\n\",\"$L20\",\"\\n\",\"$L21\",\"\\n\",\"$L22\",\"\\n\",\"$L23\",\"\\n\",\"$L24\",\"\\n\",\"$L25\",\"\\n\",\"$L26\",\"\\n\",\"$L27\",\"\\n\",\"$L28\",\"\\n\",\"$L29\",\"\\n\",\"$L2a\",\"\\n\",\"$L2b\",\"\\n\",\"$L2c\",\"\\n\",\"$L2d\",\"\\n\",\"$L2e\",\"\\n\",\"$L2f\",\"\\n\",\"$L30\",\"\\n\",\"$L31\",\"\\n\",\"$L32\",\"\\n\",\"$L33\",\"\\n\",\"$L34\",\"\\n\",\"$L35\",\"\\n\",\"$L36\",\"\\n\",\"$L37\",\"\\n\",\"$L38\",\"\\n\",\"$L39\",\"\\n\",\"$L3a\",\"\\n\",\"$L3b\",\"\\n\",\"$L3c\",\"\\n\",\"$L3d\",\"\\n\",\"$L3e\",\"\\n\",\"$L3f\",\"\\n\",\"$L40\",\"\\n\",\"$L41\",\"\\n\",\"$L42\",\"\\n\",\"$L43\",\"\\n\",\"$L44\",\"\\n\",\"$L45\",\"\\n\",\"$L46\",\"\\n\",\"$L47\",\"\\n\",\"$L48\",\"\\n\",\"$L49\",\"\\n\",\"$L4a\",\"\\n\",\"$L4b\",\"\\n\",\"$L4c\",\"\\n\",\"$L4d\",\"\\n\",\"$L4e\",\"\\n\",\"$L4f\",\"\\n\",\"$L50\",\"\\n\",\"$L51\",\"\\n\",\"$L52\",\"\\n\",\"$L53\",\"\\n\",\"$L54\",\"\\n\",\"$L55\",\"\\n\",\"$L56\",\"\\n\",\"$L57\",\"\\n\",\"$L58\",\"\\n\",\"$L59\",\"\\n\",\"$L5a\",\"\\n\",\"$L5b\",\"\\n\",\"$L5c\",\"\\n\",\"$L5d\",\"\\n\",\"$L5e\",\"\\n\",\"$L5f\",\"\\n\",\"$L60\",\"\\n\",\"$L61\",\"\\n\",\"$L62\",\"\\n\",\"$L63\",\"\\n\",\"$L64\",\"\\n\",\"$L65\",\"\\n\",\"$L66\",\"\\n\",\"$L67\",\"\\n\",\"$L68\",\"\\n\",\"$L69\",\"\\n\",\"$L6a\",\"\\n\",\"$L6b\",\"\\n\",\"$L6c\",\"\\n\",\"$L6d\",\"\\n\",\"$L6e\",\"\\n\",\"$L6f\",\"\\n\",\"$L70\",\"\\n\",\"$L71\",\"\\n\",\"$L72\",\"\\n\",\"$L73\",\"\\n\",\"$L74\"]}],\"$L75\"]}]}]\n"])</script><script>self.__next_f.push([1,"f:[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source Year\"}]\n"])</script><script>self.__next_f.push([1,"10:[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Global pharma regulatory affairs spend\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$12-18 billion/year\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory affairs as % of pharma R\u0026D spend\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"3-5%\"}],\" of ~$250B total R\u0026D\"]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory affairs outsourcing market\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$7.5-9.5 billion\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"RIM software market\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$1.8-2.5 billion\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}]]}]]}]\n"])</script><script>self.__next_f.push([1,"11:[\"$\",\"h3\",\"h3-1\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Cost of Regulatory Submission Per Drug\"}]\n"])</script><script>self.__next_f.push([1,"12:[\"$\",\"div\",\"table-1\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Component\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Cost Range\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Internal regulatory affairs staff\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$1.0-2.5M per submission\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"15-30 FTEs for 12-18 months\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRO/outsourced support\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$0.5-2.0M per submission\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Writing, compilation, publishing\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"RIM/eCTD software licenses\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$200K-800K/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Per-company, not per-submission\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total per NDA/BLA submission\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$2-5M direct costs\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Excludes opportunity cost\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total per MAA (EMA)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$3-6M direct costs\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"More complex multi-country\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"13:[\"$\",\"h3\",\"h3-2\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Cost of Regulatory Delays\"}]\n"])</script><script>self.__next_f.push([1,"14:[\"$\",\"div\",\"table-2\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimate\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Revenue loss per day of delay (blockbuster drug, \u003e$1B/year)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$2.7-8M/day\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Revenue loss per day of delay (average drug, ~$500M peak)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$1-3M/day\"}]}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average delay from CRL to re-approval\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"12-18 months\"}]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Estimated annual industry cost of regulatory delays\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$30-50 billion/year\"}]}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Cost of one FDA Complete Response Letter (to remediate)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$10-50M+ direct costs\"}]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"15:[\"$\",\"hr\",\"hr-2\",{\"className\":\"my-8 border-neutral-100\"}]\n16:[\"$\",\"h2\",\"h2-3\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"2. CURRENT SPEND TO MANAGE: RIM Software and Regulatory Outsourcing Markets\"}]\n17:[\"$\",\"h3\",\"h3-3\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Regulatory Information Management (RIM) Software Market\"}]\n"])</script><script>self.__next_f.push([1,"18:[\"$\",\"div\",\"table-3\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market size (2024)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$1.8-2.5 billion\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Projected market size (2030)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$5.5-7.0 billion\"}]}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CAGR (2024-2030)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"13-16%\"}]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key segments\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Submission management, registration tracking, health authority correspondence, labeling, document management\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"19:[\"$\",\"p\",\"p-2\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Sources: Grand View Research, Mordor Intelligence, Markets and Markets all published RIM market reports in 2023-2024 with broadly converging estimates.\"}]\n1a:[\"$\",\"h3\",\"h3-4\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Regulatory Affairs Outsourcing / CRO Market for Submissions\"}]\n"])</script><script>self.__next_f.push([1,"1b:[\"$\",\"div\",\"table-4\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory affairs outsourcing market (2024)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$7.5-9.5 billion\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Projected market size (2030)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$15-20 billion\"}]}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CAGR (2024-2030)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"11-14%\"}]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key drivers\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Increasing submission complexity, global filings, small/mid pharma outsourcing\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"1c:[\"$\",\"h3\",\"h3-5\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Breakdown of Spend Categories\"}]\n1d:[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Document authoring and medical writing\"}],\": ~30% of regulatory outsourcing\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"eCTD compilation and publishing\"}],\": ~15-20%\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Regulatory strategy consulting\"}],\": ~20%\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Post-approval lifecycle management\"}],\": ~15-20%\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Labeling and artwork management\"}],\": ~10-15%\"]}],\"\\n\"]}]\n1e:[\"$\",\"hr\",\"hr-3\",{\"className\":\"my-8 border-neutral-100\"}]\n1f:[\"$\",\"h2\",\"h2-4\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"3. COST OF INACTION: CRLs, Delays, and Review Cycles\"}]\n20:[\"$\",\"h3\",\"h3-6\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Complete Response Letters (CRLs) from FDA\"}]\n"])</script><script>self.__next_f.push([1,"21:[\"$\",\"div\",\"table-5\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source/Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRL rate for NDAs\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"15-25%\"}],\" of original NDA submissions\"]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Varies by year and therapeutic area\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRL rate for BLAs\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"20-30%\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Biologics have higher complexity\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Median cost to address a CRL\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$10-50M\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Includes additional studies, re-filing\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Time to re-submit after CRL\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"12-24 months median\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Some take 3+ years\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of CRLs citing CMC (chemistry) deficiencies\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~30-40%\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Potentially addressable by better compilation\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of CRLs citing clinical data/labeling issues\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~40-50%\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Partially addressable\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Some CRLs never result in re-approval\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~15-20%\"}],\" of CRL recipients abandon\"]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total write-off\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"22:[\"$\",\"h3\",\"h3-7\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Cost Per Day of Delayed Launch\"}]\n"])</script><script>self.__next_f.push([1,"23:[\"$\",\"div\",\"table-6\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Drug Revenue Tier\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Revenue Loss Per Day\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Annual Equivalent\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Blockbuster (\u003e$5B/yr)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$8-14M/day\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Lost from day 1 of delay\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Large ($1-5B/yr)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$2.7-8M/day\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Mid-size ($200M-1B/yr)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$0.5-2.7M/day\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Small/orphan (\u003c$200M/yr)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$100K-500K/day\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Still significant\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"24:[\"$\",\"h3\",\"h3-8\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Regulatory Review Cycle Times (2024)\"}]\n"])</script><script>self.__next_f.push([1,"25:[\"$\",\"div\",\"table-7\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Agency\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Standard Review\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Priority Review\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Accelerated/Breakthrough\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA (PDUFA)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"10-12 months\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6-8 months\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6 months (target)\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"EMA (MAA)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12-15 months\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"150 days (accelerated)\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Variable\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"PMDA (Japan)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12 months\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"9 months\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Priority review\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NMPA (China)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12-18 months\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Priority available\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Breakthrough therapy\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"26:[\"$\",\"p\",\"p-3\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Key insight\"}],\": A significant portion of review delays stem from information requests (IRs) and refuse-to-file (RTF) decisions caused by incomplete or inconsistent dossiers -- precisely the kind of errors better assembly automation could prevent.\"]}]\n27:[\"$\",\"ul\",\"ul-1\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"FDA Refuse-to-File rate: ~5-8% of NDA/BLA submissions\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Major information requests during review: affect ~40-60% of submissions\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Each information request cycle adds 1-3 months to review\"}],\"\\n\"]}]\n28:[\"$\",\"hr\",\"hr-4\",{\"className\":\"my-8 border-neutral-100\"}]\n29:[\"$\",\"h2\",\"h2-5\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"4. VOLUME FREQUENCY: Submissions, Document Sizes, and Workforce\"}]\n2a:[\"$\",\"h3\",\"h3-9\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Annual Submissions Globally\"}]\n"])</script><script>self.__next_f.push([1,"2b:[\"$\",\"div\",\"table-8\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimate\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA NDA submissions/year\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"40-55\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Novel drugs; 55 novel approvals in 2023, lower in 2024\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA BLA submissions/year\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"15-25\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Biologics\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA ANDA submissions/year (generics)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"700-900\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Less complex but high volume\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA 505(b)(2) submissions/year\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"80-120\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Modified drugs\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"EMA MAA submissions/year\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"50-80\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Centralized procedure\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total major regulatory submissions globally (all agencies)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"300-500/year\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Novel drugs, across FDA/EMA/PMDA/NMPA/TGA/HC\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Including generics and variations globally\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"5,000-10,000+/year\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Huge volume of lifecycle submissions\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Supplement/variation submissions (post-approval)\"}],\"$L76\",\"$L77\"]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"2c:[\"$\",\"h3\",\"h3-10\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Size of a Typical CTD Dossier\"}]\n"])</script><script>self.__next_f.push([1,"2d:[\"$\",\"div\",\"table-9\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Component\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Pages/Volume\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Module 1 (Regional Administrative)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"200-500 pages\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Module 2 (Summaries)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"500-2,000 pages\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Module 3 (Quality/CMC)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2,000-10,000 pages\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Module 4 (Nonclinical)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"5,000-20,000 pages\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Module 5 (Clinical)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"50,000-300,000+ pages\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Total typical NDA/BLA\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"50,000-300,000+ pages\"}]}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Some complex oncology/rare disease dossiers\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"500,000+ pages\"}]}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Electronic data volume\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"5-50+ GB per submission\"}]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"2e:[\"$\",\"h3\",\"h3-11\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Staff-Hours Per Submission\"}]\n"])</script><script>self.__next_f.push([1,"2f:[\"$\",\"div\",\"table-10\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Activity\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Hours\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory strategy and planning\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2,000-5,000 hrs\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12-24 months before filing\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Document authoring (clinical, CMC, nonclinical)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"10,000-30,000 hrs\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Medical writers + subject matter experts\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"eCTD compilation and publishing\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2,000-5,000 hrs\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Technical assembly\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Quality review and cross-referencing\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"3,000-8,000 hrs\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Consistency checks\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Total per major submission\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"20,000-50,000+ staff-hours\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Equivalent to 10-25 FTEs for 1 year\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"30:[\"$\",\"h3\",\"h3-12\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Global Regulatory Affairs Workforce\"}]\n"])</script><script>self.__next_f.push([1,"31:[\"$\",\"div\",\"table-11\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimate\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory affairs professionals globally\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"150,000-250,000\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"In-house pharma/biotech regulatory staff\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"80,000-120,000\"}]}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRO/outsourced regulatory professionals\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"40,000-80,000\"}]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory affairs consultants\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"20,000-40,000\"}]}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average salary (US, senior RA professional)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$120,000-180,000\"}]}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average salary (US, VP Regulatory)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$250,000-400,000+\"}]}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average fully loaded cost per FTE (US)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$200,000-350,000\"}]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"32:[\"$\",\"hr\",\"hr-5\",{\"className\":\"my-8 border-neutral-100\"}]\n33:[\"$\",\"h2\",\"h2-6\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"5. WHY STILL UNSOLVED: Barriers to Automation\"}]\n34:[\"$\",\"h3\",\"h3-13\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"1. Document Format Complexity (eCTD)\"}]\n35:[\"$\",\"ul\",\"ul-2\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"The \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"electronic Common Technical Document (eCTD)\"}],\" format is an XML-based hierarchical structure with extremely precise formatting, hyperlinking, and metadata requirements\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"Each health authority (FDA, EMA, PMDA, etc.) has \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"regional variations\"}],\" of eCTD with different validation rules\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"eCTD v4.0 (based on FHIR/HL7 standards) has been in development for years but adoption remains slow; most submissions still use eCTD v3.2.2\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"Leaf-level documents must be in PDF with specific bookmarking, pagination, and cross-reference standards\"}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":\"A single validation error can result in a technical rejection\"}],\"\\n\"]}]\n36:[\"$\",\"h3\",\"h3-14\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"2. Multi-System Data Sources\"}]\n37:[\"$\",\"ul\",\"ul-3\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"Clinical data comes from \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"EDC systems\"}],\" (Medidata Rave, Oracle Clinical, Veeva Vault CDMS)\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"Safety data comes from \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"pharmacovigilance systems\"}],\" (Oracle Argus, Veeva Vault Safety)\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"CMC data comes from \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"LIMS, ELN, and quality management systems\"}]]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[\"Nonclinical data from separate \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"study management systems\"}]]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":\"No single system of record; regulatory teams manually pull from 10-20+ source systems\"}],\"\\n\",[\"$\",\"li\",\"li-5\",{\"className\":\"leading-relaxed\",\"children\":\"Data formats are inconsistent (SAS datasets, PDFs, Word docs, Excel, structured data)\"}],\"\\n\"]}]\n38:[\"$\",\"h3\",\"h3-15\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"3. Regulatory Conservatism\"}]\n39:[\"$\",\"ul\",\"ul-4\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"Regulatory agencies are inherently risk-averse; \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"any error in a submission can delay approval by months\"}]]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Pharma companies fear that automated assembly could introduce errors that trigger RTF or CRL\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Validation burden\"}],\": Companies would need to validate AI/automation tools under GxP (21 CFR Part 11, EU Annex 11)\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"\\\"If it works, don't change it\\\" me"])</script><script>self.__next_f.push([1,"ntality -- legacy processes are deeply entrenched\"}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":\"Regulatory agencies themselves are slow to adopt new standards (eCTD v4.0 has been in development since ~2015)\"}],\"\\n\"]}]\n3a:[\"$\",\"h3\",\"h3-16\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"4. Liability and Accountability\"}]\n3b:[\"$\",\"ul\",\"ul-5\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"Regulatory submissions carry \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"legal liability\"}],\" (false statements to FDA are criminal offenses)\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"\\\"Who is responsible if AI assembles the dossier incorrectly?\\\" -- no clear regulatory guidance\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Companies require human review and sign-off on every document regardless of how it was created\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"GxP validation\"}],\" of any automated tool is expensive and time-consuming ($500K-2M to validate)\"]}],\"\\n\"]}]\n3c:[\"$\",\"h3\",\"h3-17\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5. Organizational Inertia\"}]\n3d:[\"$\",\"ul\",\"ul-6\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Large pharma has invested heavily in existing RIM infrastructure (Veeva, IQVIA)\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Switching costs are enormous -- migration of submission history and templates\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Regulatory affairs teams are often the most conservative function in pharma\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"Many regulatory professionals have built careers on manual expertise; resistance to automation\"}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":\"Fragmented vendor landscape means no single platform handles end-to-end\"}],\"\\n\"]}]\n3e:[\"$\",\"h3\",\"h3-18\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"6. Complexity of Content, Not Just Format\"}]\n3f:[\"$\",\"ul\",\"ul-7\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"Much of the \\\"assembly\\\" work involves \",[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"scientific judgment\"}],\" -- deciding what data to include, how to present it, what cross-references to make\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Clinical Study Reports (CSRs) require narrative interpretation of data\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Regulatory strategy decisions (what to include in Module 2 summaries) are judgment-intensive\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"This is not just a formatting/compilation problem; it involves deep domain expertise\"}],\"\\n\"]}]\n40:[\"$\",\"hr\",\"hr-6\",{\"className\":\"my-8 border-neutral-100\"}]\n41:[\"$\",\"h2\",\"h2-7\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"6. WILLINGNESS TO PAY SIGNALS\"}]\n42:[\"$\",\"h3\",\"h3-19\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"What Pharma Pays for Regulatory Affairs Staff\"}]\n"])</script><script>self.__next_f.push([1,"43:[\"$\",\"div\",\"table-12\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Role\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"US Salary Range\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory Affairs Specialist\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$85,000-130,000\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Entry to mid-level\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Senior Regulatory Affairs Manager\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$130,000-180,000\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Director, Regulatory Affairs\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$180,000-260,000\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"VP, Regulatory Affairs\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$250,000-450,000+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Top 20 pharma\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Chief Regulatory Officer\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$400,000-700,000+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"C-suite equivalent\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Fully loaded cost (benefits, overhead)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"1.5-2x salary\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"44:[\"$\",\"h3\",\"h3-20\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"What Pharma Pays for RIM Software\"}]\n"])</script><script>self.__next_f.push([1,"45:[\"$\",\"div\",\"table-13\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Vendor/Product\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimated Annual Cost\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Veeva Vault RIM\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$500K-5M+/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Depends on modules, users, enterprise size\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"IQVIA RIM Suite\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$300K-3M+/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Competitive with Veeva\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Lorenz docuBridge\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$200K-1.5M/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Strong in eCTD publishing\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Extedo (Amplexor/Acolad)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$200K-1M/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"EU-focused\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NNIT Regulatory Platform\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$200K-1M/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Nordic/EU market\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total enterprise RIM spend (top 20 pharma)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$3-10M/year per company\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Multiple modules and tools\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Mid-size pharma (top 50)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$500K-3M/year per company\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$undefined\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Small/emerging biotech\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$100K-500K/year\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Often outsource instead\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"46:[\"$\",\"h3\",\"h3-21\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"What Pharma Pays for Regulatory CROs\"}]\n"])</script><script>self.__next_f.push([1,"47:[\"$\",\"div\",\"table-14\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Service\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Cost Range\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"eCTD publishing per submission\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$50K-200K\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Technical publishing only\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Full NDA/BLA regulatory support\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$500K-3M+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Strategy through filing\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory writing (CSRs, summaries)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$300-600/hour\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Senior medical writers\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Ongoing lifecycle management\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$200K-1M/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Variations, renewals, annual reports\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"48:[\"$\",\"p\",\"p-4\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Key WTP Signal\"}],\": Top 20 pharma companies each spend \",[\"$\",\"strong\",\"strong-1\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$50-150M+/year\"}],\" on regulatory affairs (staff + CRO + software combined). They have demonstrated willingness to pay premium prices for solutions that reduce risk and accelerate timelines. Even a 10-20% efficiency gain would be worth \",[\"$\",\"strong\",\"strong-2\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$5-30M/year per company\"}],\".\"]}]\n49:[\"$\",\"hr\",\"hr-7\",{\"className\":\"my-8 border-neutral-100\"}]\n4a:[\"$\",\"h2\",\"h2-8\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"7. MARKET GROWTH RATE\"}]\n4b:[\"$\",\"h3\",\"h3-22\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"RIM Software Market CAGR\"}]\n"])</script><script>self.__next_f.push([1,"4c:[\"$\",\"div\",\"table-15\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Market\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"CAGR\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Period\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Grand View Research\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"RIM Software\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"14.5%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024-2030\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Mordor Intelligence\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"RIM Software\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"13.8%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024-2029\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Markets and Markets\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"RIM Software\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"15.2%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2023-2028\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Precedence Research\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory Affairs Outsourcing\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12.5%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024-2030\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Fortune Business Insights\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory Technology (RegTech) in Pharma\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"16.0%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024-2032\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"4d:[\"$\",\"h3\",\"h3-23\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Key Growth Drivers\"}]\n"])</script><script>self.__next_f.push([1,"4e:[\"$\",\"ol\",\"ol-0\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Increasing regulatory complexity\"}],\": More global submissions, more complex molecules (cell/gene therapy, ADCs)\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"eCTD mandates expanding\"}],\": More countries mandating electronic submissions\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"AI/ML integration\"}],\": New capabilities driving upgrades and new spend\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Biotech funding recovery\"}],\": More drugs entering late-stage development post-2023 funding recovery\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"China/emerging market filings\"}],\": Growing regulatory requirements in NMPA, ANVISA, etc.\"]}],\"\\n\",[\"$\",\"li\",\"li-5\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Post-COVID regulatory modernization\"}],\": Agencies investing in digital infrastructure\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"4f:[\"$\",\"h3\",\"h3-24\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Broader Context\"}]\n"])</script><script>self.__next_f.push([1,"50:[\"$\",\"div\",\"table-16\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Market\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"2024 Size\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"2030 Projected\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"CAGR\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Global pharma R\u0026D spend\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$250B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$350B\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~6%\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical trial management software\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$2B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$4B\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~12%\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Pharmacovigilance market\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$7B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$14B\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~12%\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory information management\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$2B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$6B\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~14%\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Total addressable for reg submission automation\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~$3-5B\"}]}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~$8-12B\"}]}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~14-16%\"}]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"51:[\"$\",\"hr\",\"hr-8\",{\"className\":\"my-8 border-neutral-100\"}]\n52:[\"$\",\"h2\",\"h2-9\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"8. KEY PLAYERS TODAY\"}]\n53:[\"$\",\"h3\",\"h3-25\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Veeva Systems (Vault RIM) -- Market Leader\"}]\n"])</script><script>self.__next_f.push([1,"54:[\"$\",\"div\",\"table-17\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total Veeva revenue (FY2025, ended Jan 2025)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$2.7 billion\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Veeva Vault (all modules) revenue\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$1.8 billion (subscription)\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Vault RIM estimated revenue\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$300-500M\"}],\" (estimated, not separately disclosed)\"]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market position\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"#1 in cloud RIM; dominant in large pharma\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key products\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Vault Registrations, Vault Submissions, Vault Submissions Publishing, Vault Submissions Archive\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Customers\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"19 of top 20 pharma companies use Veeva\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Strategy\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"End-to-end regulatory platform; expanding into AI-assisted authoring\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"55:[\"$\",\"h3\",\"h3-26\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"IQVIA (RIM Suite)\"}]\n"])</script><script>self.__next_f.push([1,"56:[\"$\",\"div\",\"table-18\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total IQVIA revenue (2024)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$15 billion\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Technology \u0026 Analytics Solutions segment\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$6 billion\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory solutions estimated revenue\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$200-400M\"}],\" (estimated)\"]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key products\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"IQVIA RIM Smart, Regulatory Publishing, Regulatory Intelligence\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market position\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"#2 behind Veeva; strong in data/analytics integration\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"57:[\"$\",\"h3\",\"h3-27\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Lorenz Life Sciences (docuBridge)\"}]\n"])</script><script>self.__next_f.push([1,"58:[\"$\",\"div\",\"table-19\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Estimated revenue\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$50-100M\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Ownership\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acquired by Instem (now Arxada/separate)\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key product\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"docuBridge -- leading standalone eCTD publishing tool\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market position\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Strong in mid-market; popular in EU\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Customers\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"300+ pharma/biotech companies\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"59:[\"$\",\"h3\",\"h3-28\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"AMPLEXOR / Acolad Group (Extedo)\"}]\n"])</script><script>self.__next_f.push([1,"5a:[\"$\",\"div\",\"table-20\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Estimated regulatory solutions revenue\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$50-80M\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key products\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Extedo eCTDmanager, RIMS, GlobalSubmit\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market position\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Strong in EU regulatory submissions\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acquired by\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acolad Group (2020)\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"5b:[\"$\",\"h3\",\"h3-29\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Other Notable Players\"}]\n"])</script><script>self.__next_f.push([1,"5c:[\"$\",\"div\",\"table-21\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Product\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Estimated Revenue\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Notes\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Parexel (regulatory consulting)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRO services\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$500M+ (reg segment)\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Part of larger CRO\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NNIT\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory platform\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$30-50M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Nordic/EU focus\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Freyr Solutions\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory services/tech\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$80-120M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Fast-growing; India-based\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Navitas Life Sciences (TAKE Solutions)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory services\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$60-100M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Outsourced RA services\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Generis (CARA)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Submission management\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$20-40M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"UK-based\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Samarind\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory tracking\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$10-20M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"EU focus\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Glemser Technologies\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"eCTD publishing\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$10-20M\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Niche player\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"5d:[\"$\",\"h3\",\"h3-30\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Emerging AI-Focused Entrants (2023-2025)\"}]\n"])</script><script>self.__next_f.push([1,"5e:[\"$\",\"div\",\"table-22\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Focus\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Funding/Stage\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Arine\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI regulatory intelligence\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Series B\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Rheos AI / various startups\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI-assisted regulatory writing\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Seed-Series A\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Veeva AI (internal)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI features within Vault RIM\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Announced 2024\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"IQVIA AI (internal)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI for regulatory intelligence\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"In development\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Various generative AI plays\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CSR automation, summary generation\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Early stage\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"5f:[\"$\",\"hr\",\"hr-9\",{\"className\":\"my-8 border-neutral-100\"}]\n60:[\"$\",\"h2\",\"h2-10\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"9. KEY SOURCES\"}]\n61:[\"$\",\"h3\",\"h3-31\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Market Research Reports (Paywalled -- Titles and Publishers)\"}]\n"])</script><script>self.__next_f.push([1,"62:[\"$\",\"ol\",\"ol-1\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Grand View Research\"}],\" -- \\\"Regulatory Information Management Software Market Size, Share \u0026 Trends Analysis Report\\\" (2024)\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market\",\"children\":\"https://www.grandviewresearch.com/industry-analysis/regulatory-information-management-software-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Mordor Intelligence\"}],\" -- \\\"Regulatory Information Management Market - Growth, Trends, and Forecasts\\\"\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.mordorintelligence.com/industry-reports/regulatory-information-management-market\",\"children\":\"https://www.mordorintelligence.com/industry-reports/regulatory-information-management-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Markets and Markets\"}],\" -- \\\"Regulatory Information Management Market\\\"\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.marketsandmarkets.com/Market-Reports/regulatory-information-management-market\",\"children\":\"https://www.marketsandmarkets.com/Market-Reports/regulatory-information-management-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Precedence Research\"}],\" -- \\\"Regulatory Affairs Outsourcing Market\\\"\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.precedenceresearch.com/regulatory-affairs-outsourcing-market\",\"children\":\"https://www.precedenceresearch.com/regulatory-affairs-outsourcing-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Fortune Business Insights\"}],\" -- \\\"Pharmaceutical Regulatory Technology Market\\\"\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fortunebusinessinsights.com/regulatory-information-management-market\",\"children\":\"https://www.fortunebusinessinsights.com/regulatory-information-management-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"63:[\"$\",\"h3\",\"h3-32\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Company Filings and Investor Relations\"}]\n"])</script><script>self.__next_f.push([1,"64:[\"$\",\"ol\",\"ol-2\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Veeva Systems SEC Filings (10-K, 10-Q)\"}],\" -- Revenue breakdowns, Vault platform metrics\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://ir.veeva.com/sec-filings\",\"children\":\"https://ir.veeva.com/sec-filings\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"IQVIA Annual Report 2024\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://ir.iqvia.com/annual-reports\",\"children\":\"https://ir.iqvia.com/annual-reports\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Veeva Systems Investor Day 2024\"}],\" -- Product roadmap including AI features\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://ir.veeva.com/events-and-presentations\",\"children\":\"https://ir.veeva.com/events-and-presentations\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"65:[\"$\",\"h3\",\"h3-33\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"FDA Data Sources\"}]\n"])</script><script>self.__next_f.push([1,"66:[\"$\",\"ol\",\"ol-3\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"FDA Novel Drug Approvals\"}],\" -- Annual approval counts\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-fda\",\"children\":\"https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-fda\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"FDA PDUFA Performance Reports\"}],\" -- Review times, CRL rates, RTF rates\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fda.gov/about-fda/user-fee-reports/pdufa-performance-reports\",\"children\":\"https://www.fda.gov/about-fda/user-fee-reports/pdufa-performance-reports\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"FDA CDER Annual Reports\"}],\" -- Submission volumes\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder\",\"children\":\"https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"67:[\"$\",\"h3\",\"h3-34\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Industry Publications and Analysis\"}]\n"])</script><script>self.__next_f.push([1,"68:[\"$\",\"ol\",\"ol-4\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Tufts Center for the Study of Drug Development\"}],\" -- Cost of drug development, regulatory timelines\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://csdd.tufts.edu/\",\"children\":\"https://csdd.tufts.edu/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Deloitte Life Sciences Report\"}],\" -- \\\"Measuring the Return from Pharmaceutical Innovation\\\" (annual)\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html\",\"children\":\"https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"McKinsey \u0026 Company\"}],\" -- \\\"How pharma can accelerate business impact from advanced analytics\\\" and regulatory efficiency articles\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.mckinsey.com/industries/life-sciences/our-insights\",\"children\":\"https://www.mckinsey.com/industries/life-sciences/our-insights\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"RAPS (Regulatory Affairs Professionals Society)\"}],\" -- Workforce data, salary surveys\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.raps.org/\",\"children\":\"https://www.raps.org/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"DIA (Drug Information Association)\"}],\" -- Regulatory submission best practices\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.diaglobal.org/\",\"children\":\"https://www.diaglobal.org/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-5\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"ICH (International Council for Harmonisation)\"}],\" -- eCTD standards and M8 guidelines\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.ich.org/page/ctd\",\"children\":\"https://www.ich.org/page/ctd\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"69:[\"$\",\"h3\",\"h3-35\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Analyst and News Sources\"}]\n"])</script><script>self.__next_f.push([1,"6a:[\"$\",\"ol\",\"ol-5\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Evaluate Pharma\"}],\" -- Pipeline analytics and drug revenue forecasts\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.evaluate.com/\",\"children\":\"https://www.evaluate.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"BioPharma Dive\"}],\" -- Industry news on regulatory technology\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.biopharmadive.com/\",\"children\":\"https://www.biopharmadive.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Fierce Pharma\"}],\" -- Drug approval news, CRL tracking\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fiercepharma.com/\",\"children\":\"https://www.fiercepharma.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Pink Sheet (Informa)\"}],\" -- FDA regulatory intelligence\",\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://pink.citeline.com/\",\"children\":\"https://pink.citeline.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"6b:[\"$\",\"hr\",\"hr-10\",{\"className\":\"my-8 border-neutral-100\"}]\n6c:[\"$\",\"h2\",\"h2-11\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"Summary and Opportunity Assessment\"}]\n6d:[\"$\",\"h3\",\"h3-36\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"The Opportunity in Numbers\"}]\n"])</script><script>self.__next_f.push([1,"6e:[\"$\",\"div\",\"table-23\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Dimension\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total addressable market (regulatory submission assembly)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$3-5B currently, growing to $8-12B by 2030\"}]}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Current automation penetration\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"\u003c15%\"}],\" of assembly workflow is automated\"]}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Potential efficiency gain from AI automation\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"30-60% reduction in staff-hours\"}]}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Value per large pharma customer\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$5-30M/year in savings\"}]}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Number of large pharma targets (\u003e$10B revenue)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~25-30 companies\"}]}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Number of mid-size pharma/biotech targets\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"~200-500 companies\"}]}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Willingness to pay (validated by current spend)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"$$500K-5M+/year per enterprise\"}]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"6f:[\"$\",\"h3\",\"h3-37\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Why Now\"}]\n"])</script><script>self.__next_f.push([1,"70:[\"$\",\"ol\",\"ol-6\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Generative AI maturity\"}],\" (2023-2025): LLMs can now understand and generate regulatory-quality scientific text\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"eCTD v4.0 transition\"}],\": Creates a natural upgrade cycle and openness to new tools\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Increasing submission complexity\"}],\": Cell/gene therapies, combination products require more sophisticated assembly\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Talent shortage\"}],\": Not enough experienced regulatory professionals; automation is becoming necessary\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Regulatory agency modernization\"}],\": FDA and EMA investing in digital submission infrastructure\"]}],\"\\n\",[\"$\",\"li\",\"li-5\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Demonstrated ROI\"}],\": Even partial automation of document QC, cross-referencing, and formatting has shown 20-40% time savings in pilot programs\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"71:[\"$\",\"h3\",\"h3-38\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Key Risk Factors\"}]\n72:[\"$\",\"ul\",\"ul-8\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Regulatory validation burden\"}],\": Any AI tool used in submissions needs GxP validation\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Incumbent lock-in\"}],\": Veeva's dominance creates high switching costs\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Conservative buyers\"}],\": Regulatory affairs leaders prioritize risk avoidance over efficiency\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Liability concerns\"}],\": Unclear accountability framework for AI-assembled submissions\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Long sales cycles\"}],\": Enterprise pharma procurement can take 12-24 months\"]}],\"\\n\"]}]\n73:[\"$\",\"hr\",\"hr-11\",{\"className\":\"my-8 border-neutral-100\"}]\n74:[\"$\",\"p\",\"p-5\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"em\",\"em-0\",{\"children\":\"Report compiled February 2026. Market size estimates represent ranges from multiple analyst sources (2023-2025 publications). Revenue estimates for private companies and product-level breakdowns are analyst estimates based on publicly available information. All figures should be independently verified against cited sources.\"}]}]\n75:[\"$\",\"div\",null,{\"className\":\"mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8\",\"children\":[[\"$\",\"$Le\",null,{\"href\":\"/reports/market-opportunity-research\",\"className\":\"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group\",\"children\":[[\"$\",\"span\",null,{\"className\":\"transition-transform group-hover:-translate-x-0.5\",\"children\":\"←\"}],\"Back to AI Market Opportunity Research\"]}],[\"$\",\"span\",null,{\"className\":\"text-neutral-300\",\"children\":\"·\"}],[\"$\",\"$Le\",null,{\"href\":\"/research\",\"className\":\"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group\",\"children\":[[\"$\",\"span\",null,{\"className\":\"transition-transform group-hover:-translate-x-0.5\",\"children\":\"←\"}],\"Back to Research\"]}]]}]\n"])</script><script>self.__next_f.push([1,"76:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"10,000-20,000+/year\"}]}]\n77:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Ongoing lifecycle management\"}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}]]\n"])</script><script>self.__next_f.push([1,"78:I[27201,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"IconMark\"]\n8:null\nc:[[\"$\",\"title\",\"0\",{\"children\":\"Regulatory Submission Assembly for Drug Approvals — AI Market Opportunity Research\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Pharma spends years manually compiling FDA/EMA dossiers; $5–20M per NDA/BLA submission. Regulatory affairs spend is ~$12–15B/year; RIM software market is $3.2–4B.\"}],[\"$\",\"meta\",\"2\",{\"property\":\"og:title\",\"content\":\"Rigid Body Dynamics AI — AI That Does the Work for You\"}],[\"$\",\"meta\",\"3\",{\"property\":\"og:description\",\"content\":\"We research what's next in AI and make it accessible — one problem at a time.\"}],[\"$\",\"meta\",\"4\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"5\",{\"name\":\"twitter:title\",\"content\":\"Rigid Body Dynamics AI — AI That Does the Work for You\"}],[\"$\",\"meta\",\"6\",{\"name\":\"twitter:description\",\"content\":\"We research what's next in AI and make it accessible — one problem at a time.\"}],[\"$\",\"link\",\"7\",{\"rel\":\"icon\",\"href\":\"/rigidbodydynamicsai/favicon.ico?favicon.0b3bf435.ico\",\"sizes\":\"256x256\",\"type\":\"image/x-icon\"}],[\"$\",\"link\",\"8\",{\"rel\":\"icon\",\"href\":\"/icon?64afa28a3da3d704\",\"alt\":\"$undefined\",\"type\":\"image/png\",\"sizes\":\"32x32\"}],[\"$\",\"$L78\",\"9\",{}]]\n"])</script></body></html>